Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Drugs and adverse drug reactions: how worried should we be?

Bates DW.

JAMA. 1998 Apr 15;279(15):1216-7. No abstract available.

PMID:
9555764
2.

Adverse drug reactions in hospitalized patients.

Hui KK.

JAMA. 1998 Nov 25;280(20):1742-3; author reply 1743-4. No abstract available.

PMID:
9842944
3.

Adverse drug reactions in hospitalized patients.

Hanzlick R, Baker PB, Hutchins GM.

JAMA. 1998 Nov 25;280(20):1742; author reply 1743-4. No abstract available.

PMID:
9842943
4.

Adverse drug reactions in hospitalized patients.

Bush T.

JAMA. 1998 Nov 25;280(20):1742; author reply 1743-4. No abstract available.

PMID:
9842942
5.

Adverse drug reactions in hospitalized patients.

Kravitz GR.

JAMA. 1998 Nov 25;280(20):1741; author reply 1743-4. No abstract available.

PMID:
9842941
6.

Adverse drug reactions in hospitalized patients.

Fremont-Smith K.

JAMA. 1998 Nov 25;280(20):1741; author reply 1743-4. No abstract available.

PMID:
9842940
7.

Adverse reporting on adverse reactions.

Bains N, Hunter D.

CMAJ. 1999 Feb 9;160(3):350-1. No abstract available.

8.

The importance of adverse reactions in drug regulation.

Dukes MN.

Drug Saf. 1990 Jan-Feb;5(1):3-6. No abstract available.

PMID:
2310512
9.

Safety of newly approved drugs: implications for prescribing.

Temple RJ, Himmel MH.

JAMA. 2002 May 1;287(17):2273-5. No abstract available.

PMID:
11980528
10.

New law in Germany compensates patients for drug side-effects.

Orellana C.

Lancet. 2002 Aug 10;360(9331):471. No abstract available.

PMID:
12241734
11.

Discovering adverse drug reactions.

Lasagna L.

JAMA. 1983 Apr 22-29;249(16):2224-5. No abstract available.

PMID:
6339764
12.

Unforeseeable adverse drug reactions: who should pay?

Loveland D.

Med Law. 1985;4(4):327-36. No abstract available.

PMID:
4046760
13.

Unwanted drug effects: whose responsibility?

[No authors listed]

Lancet. 1979 Jul 7;2(8132):21. No abstract available.

PMID:
87894
14.

FDA weighs communicating drug-related risk to patients.

Stephenson J.

JAMA. 1999 Aug 11;282(6):515. No abstract available. Erratum in: JAMA 1999 Oct 20;282(15):1425.

PMID:
10450699
15.

The role of litigation in defining drug risks.

Kesselheim AS, Avorn J.

JAMA. 2007 Jan 17;297(3):308-11. No abstract available.

PMID:
17227983
16.

Review of the processes for FDA oversight of drugs, medical devices, and combination products.

Sweet BV, Schwemm AK, Parsons DM.

J Manag Care Pharm. 2011 Jan-Feb;17(1):40-50. Review. No abstract available.

17.

Post-marketing surveillance of prescription drug safety: past, present, and future.

Chen BK, Yang YT.

J Leg Med. 2013;34(2):193-213. doi: 10.1080/01947648.2013.800797. No abstract available.

PMID:
23980746
18.

Trends in boxed warnings and withdrawals for novel therapeutic drugs, 1996 through 2012.

Cheng CM, Shin J, Guglielmo BJ.

JAMA Intern Med. 2014 Oct;174(10):1704-5. doi: 10.1001/jamainternmed.2014.4854. No abstract available.

PMID:
25127107
19.

The new EU legislation on pharmacovigilance and changing models for drug development.

Callréus T.

Drug Saf. 2011 Jun 1;34(6):529-30; author reply 530-1. doi: 10.2165/11592380-000000000-00000. No abstract available.

PMID:
21585224
20.

[Prescriptions: how does the pharmacy check for plausibility?].

Ewering I.

Hautarzt. 2015 Dec;66(12):967-9. doi: 10.1007/s00105-015-3714-x. German. No abstract available.

PMID:
26471038

Supplemental Content

Support Center